Endothelial cell genome edited with CRISPR for the first time

A team from the laboratory of youyang zhao, in Chicago Children’s Research Institute (USA), developed a Nano-particle to be able to manage gene editing technology CRISPR Cas9 to endothelial cells.

According to the authors, this is the first time that the genome of these cells that line the cells has been edited. blood vessel wallsThe usual way of administering CRISPR Cas9 – through a virus – does not work with endothelial cells. The results of the work were published in the journal. Cell Reports.

“The nanoparticle we developed is a powerful new system for genome editing of vascular endothelial cells and can be used to treat many diseases, including acute respiratory distress syndrome caused by severe COVID-19,” said Zhao, lead author of the study.

The nanoparticle we developed is a powerful new system for genome editing in vascular endothelial cells and can be used to treat many diseases.

Youyang Zhao, lead author of the study

Inhibit vascular injury

The expert explains that this nanoparticle can “introduce genes to inhibit vascular damage, promote vascular repair, correct genetic mutations and turn genes on or off to restore normal function. It also allows us to edit multiple genes at the same time. This is an important advance in the treatment of any disease caused by a endothelial dysfunction”.

This dysfunction is at the origin of many diseases, such as coronary artery disease, stroke, bronchopulmonary dysplasia and pulmonary arterial hypertension.

Zhao claims that genome editing in endothelial cells may even treat cancer “by cutting off the tumor’s blood supply or blocking metastasis,” and also highlights the importance of this advance for cardiovascular research.

Read Also:  Is nuclear energy clean and ecological?

The authors highlight that they achieved “excellent results in a mouse model”. The nanoparticle containing the CRISPR Cas9 plasmid DNA was introduced through a single intravenous injection and it took a few days to show its effectiveness, they explain. They also clarify that it will now be necessary to perform pre-clinical tests before starting clinical trials.

Reference:

Youyang Zhao and everything. Cell Reports, 2022

Rights: Creative Commons.

.

Recent Articles

Related News

Leave A Reply

Please enter your comment!
Please enter your name here